Please assess the completion status of the following clinical trial:

Trial Title: Does a Migraine Medication Decrease Rotational Motion Sickness in People Suffering From Migraines?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* History of motion sickness~* Currently suffering from migraines with at least 2 episodes during the previous 12 months~* Previous use and tolerance to triptans~Exclusion Criteria:~* Current tobacco user~* History of or current hypertension, cardiac disease, arrhythmia, hypercholesterolemia, hemiplegic/basilar migraine, stroke, diabetes, vascular disease or kidney disease~* Family history of early myocardial infarction (first-degree relative \< 45 years old at time of event)~* Constant dizziness or constant vestibular symptoms~* History of ear, nose and throat (ENT) disease, e.g. Meniere's disease~* Current treatment with propranolol or medications that would preclude use of a triptan(e.g. ergotamine)~* Major vestibular abnormality found on screening~* Testing positive on over-the-counter pregnancy test~* Taken an Monamine Oxidase (MAO) inhibitor within two weeks of testing~* Allergy or intolerance to gelatin~* Corrected visual acuity of \> 20/40 O.U.~* Women who are pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- With Vertigo; Placebo - Rizatriptan (Type: OTHER): This group received placebo on visit 1 and Rizatriptan on visit 2.
- With Vertigo; Rizatriptan - Placebo (Type: OTHER): These subjects received Rizatriptan on visit 1 and placebo on visit 2.
- Without Vertigo; Placebo - Rizatriptan (Type: OTHER): This group received placebo on visit 1 and Rizatriptan on visit 2.
- Without Vertigo; Rizatriptan-Placebo (Type: OTHER): This group received Rizatriptan on visit 1 and placebo on visit 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).